Autoinjectors Industry Size

The report "Autoinjectors Market by Usage (Disposable, Reusable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Obesity, Anaphypaxis, Multiple Sclerosis), Route of Administration (SC, IM), Volume (<3ml, >3ml) - Global Forecast to 2030 ", is projected to to expand to a value of USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is projected to surge to a value of  USD 134.27 billion in 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%. Some of the prominent factors driving the growth of market are adequate reimbursement policies and rise in number of regulatory approvals for autoinjectors.

Browse 527 market data Tables and 75 Figures spread through 382 Pages and in-depth TOC on "Autoinjectors Market by Usage (Disposable, Reusable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Obesity, Anaphypaxis, Multiple Sclerosis), Route of Administration (SC, IM), Volume (<3ml, >3ml) - Global Forecast to 2030 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/autoinjector-market-173991724.html

The Rheumatoid Arthritis accounted for the dominant share in 2023.

Based on the therapy area, the autoinjectors market is divided into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, obesity, and other therapy areas. In 2023, the rheumatoid arthritis segment dominated the autoinjectors market and obesity segment is anticipated to grow at highest CAGR during the forecast period. Growing prevalence of rheumatoid arthritis and availability of autoinjectors for the treatment of this condition are some of the major factors driving the growth of the market. Obesity segment is likely to grow at faster pace owing to launch of novel products and rise in adoption of autoinjectors for weight management. As of August 2024, according to Australia's Therapeutic Goods Administration Wegovy (semaglutide), will be available in Australia from early August 2024.

Reusable autoinjectors is likely to grow at significant CAGR during the forecast period for 2024-2030.

Based on the usage, the autoinjectors market is further categorized into reusable and disposable autoinjectors. In 2023, the disposable segment accounted for the fastest-growing share of the usage segment of autoinjectors market. Ease of use, growing demand in self-administration and reduced risk of cross-contamination or infection is driving the growth of the disposable autoinjectors market. Innovations in reusable autoinjector such as ergonomic designs, digital interfaces, and enhanced safety features is rising adoption of reusable autoinjectors in developing countries.

Europe: The second-largest region in the autoinjectors market.

The European autoinjectors market held second-largest market share autoinjectors market globally. The favorable reimbursement and regulatory scenario is giving momentum to the market growth in European region. Furthermore, rising prevalence of chronic diseases and increasing adoption of autoinjectors among patient population is likely to boost the market growth in the region.

Furthermore, presence of key market players such as SHL Medical, Ypsomed is likely to contribute to the growth of the market.

Autoinjectors market players for devices include SHL Medical AG (Switzerland), Ypsomed AG (Switzerland), Becton, Dickinson and Company (BD) (US), Recipharm AB (Sweden), West Pharmaceutical Services, Inc.(US), Phillips-Medisize (US), Halozyme, Inc. (US), Owen Mumford Ltd. (UK), Gerresheimer AG (Germany), Haselmeier (Germany), Oval Medical Technologies Ltd. (UK), Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China), Elcam Drug Delivery Devices (Israel), Crossject (France), Jabil, Inc. (US), Congruence Medical Solutions LLC (US), Midas Pharma GMBH (Germany). Some of the major market players for finished formulations covered in this chapter include Abbvie Inc. (US), Eli Lilly and Company (US), Amgen Inc. (US), Novo Nordisk A/S (Denmark), Jonhson & Jonhson Services Inc. (US), Sanofi (France), GSK plc (UK).

Don’t miss out on business opportunities in Autoinjectors Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]